Table 2 Patient characteristics according to IDH mutation. Median age was comparable in mutated and wild-type groups. The IDH mutation rate was not different in localized (43%) vs. metastatic (50%) patients; while it was significantly higher in G3 (69%) than in G2 (37%) tumors (p=0.0390)
From: IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience
|  | all sample = 54 | IDHmut N = 24 | IDHwt N = 30 | P value |
|---|---|---|---|---|
Age, median(range) | 63 (17–85) | 60 (33–85) | 64 (17–79) | 0.2889 |
Site, n (%) | Â | Â | Â | Â |
Extremity | 25 (46%) | 14 (56%) | 11 (44%) | 0.2357 |
Pelvis | 18 (33%) | 7 (39%) | 11 (61%) | Â |
Other | 11 (21%) | 3 (27%) | 8 (73%) | Â |
Grade, n (%) | Â | Â | Â | Â |
G2 | 41 (76%) | 15 (37%) | 26 (63%) | 0.0390 |
G3 | 13 (24%) | 9 (69%) | 4 (31%) | Â |
Stage, n (%) | Â | Â | Â | Â |
Localized | 40 (74%) | 17 (43%) | 23 (57%) | 0.6269 |
Metastatic | 14 (26%) | 7 (50%) | 7 (50%) | Â |
Margins, n (%) | Â | Â | Â | Â |
Wide | 39 (75%) | 17 (44%) | 22 (56%) | 0.5206 |
Not-wide | 13 (25%) | 7 (54%) | 6 (46%) | Â |